Live Quote · NASDAQNAMSHealthcare· Biotechnology

NewAmsterdam Pharma Company N.V.

$34.83 0.97%($-0.34)
TickerSpark Score
61/100
Mixed
45
Valuation
40
Profitability
55
Growth
84
Health
80
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NAMS research report →

52-Week Range68% of range
Low
$19.22
Current
$34.83
High
$42.20

About the company

NewAmsterdam Pharma Company N. V. , a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

CEO
Michael Davidson
IPO
2021
Employees
100
HQ
Naarden, NH, NL

Price Chart

+83.70% · this period
$41.45$30.21$18.96Jul 02Dec 31Jul 02
Valuation
Market Cap
$4.07B
P/E
-19.24
P/S
180.45
P/B
6.34
EV/EBITDA
-17.01
Div Yield
0.00%
Profitability
Gross Margin
97.52%
Op Margin
-953.59%
Net Margin
-942.76%
ROE
-29.80%
ROIC
-32.35%
Growth & Income
Revenue
$22.50M · -50.61%
Net Income
$-203,819,000 · 15.64%
EPS
$-1.75 · 31.64%
Op Income
$-225,683,000
FCF YoY
7.04%
Performance & Tape
52W High
$42.20
52W Low
$19.22
50D MA
$32.73
200D MA
$33.61
Beta
0.08
Avg Volume
1.29M

Get TickerSpark's AI analysis on NAMS

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 22, 26Kooij Louise Frederikaother15,000
Jun 22, 26Kooij Louise Frederikaother25,000
Jun 22, 26Kooij Louise Frederikaother25,000
Jun 22, 26Kooij Louise Frederikaother15,000
Jun 22, 26Kooij Louise Frederikasell39,700
Jun 22, 26Kooij Louise Frederikasell300
May 26, 26Kooij Louise Frederikaother5,000
May 26, 26Kooij Louise Frederikaother60,000
May 26, 26Kooij Louise Frederikaother60,000
May 26, 26Kooij Louise Frederikaother5,000
Coverage · NAMS

Our NAMS coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on NAMS yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate NAMS report →
Internal Compare

Similar companies

Peers in the same neighborhood.